Maryam Tabatabai, PharmD, associate vice president of clinical information, offers predictions about forthcoming drug approvals, the latest on a new voucher pilot, updated biosimilar guidance and more

New report details the latest on GLP-1s

publications The evolution of GLP-1s July 31, 2025 Prime's clinical experts share their perspectives on developing a holistic, individualized strategy to capitalize on opportunities and improve...

Following real-world analysis of GLP-1 drugs for weight loss, Prime/Magellan Rx releases new video about GLP-1 research

Findings also show improved persistence with high-potency, obesity-approved GLP-1 products

Jessica Johnson, clinical consultant at Prime Therapeutics, shares more about common GLP-1 fraud schemes

Real-world study of GLP-1 patients continues to deliver leading insights

David Lassen, vice president of pharmacy clinical services, and Marci Chodroff, vice president and medical director at Prime Therapeutics, share more about the latest GLP-1 insights from ongoing...

Among the key findings from the study — among 4,066 members, Prime/MRx found 1 in 3 stayed on their GLP-1 and 27% took their medication as intended

Jessica Johnson, clinical consultant at Prime's Special Investigations Unit, shares how to identify fake GLP-1s

Forbes: Injectable glucagon-like peptide-1 agonists, or GLP-1s, were first approved as diabetes medications 20 years ago

Ben Urick, senior director of health outcomes, and Landon Marshall, health outcomes research principal, share more about their educational session and research poster on GLP-1s

BioSpace: While drug developers work to mitigate the side effects associated with GLP-1–based obesity drugs, recent studies reveal that myriad variables are causing patients to stop treatment

Real-world, integrated data follows-up on previous insights, analytics.

Develop a holistic GLP-1 strategy An evidence-based approach to GLP-1 drugs helps you implement custom strategies that promote clinically appropriate use and consider affordability, long-term value...

Cover image for Quarterly Drug Pipeline: January 2025 Updates on promising therapies in development, focusing on drugs nearing FDA approval Prime Therapeutics /quarterly-drug-pipeline-january-2025...

Jessica Johnson, clinical consultant, shares how the Special Investigations Unit at Prime helps identify cases of fraud

cover image for Quarterly Drug Pipeline: October 2024 Quarterly Drug Pipeline: October 2024 Prime Therapeutics /quarterly-drug-pipeline-october-2024 Prime Therapeutics’ Quarterly Drug Pipeline...

Cover image for Quarterly Drug Pipeline: April 2025 Clinical insights and competitive intelligence on anticipated drugs in development Prime Therapeutics /quarterly-drug-pipeline-april-2025 Prime...

Cover image for Quarterly Drug Pipeline: October 2025 Clinical insights and competitive intelligence on anticipated drugs in development Prime Therapeutics /quarterly-drug-pipeline-october-2025...